Multiple Sclerosis Pipeline Review Report of 178 Companies

Jul 14, 2016, 06:00 ET from ReportsnReports

PUNE, India, July 14, 2016 /PRNewswire/ -- adds "Multiple Sclerosis - Pipeline Review, H1 2016" market research report to its store providing an overview of the Multiple Sclerosis's therapeutic pipeline complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Sclerosis and special features on late-stage and discontinued projects.

Complete report on H1 2016 pipeline review of Multiple Sclerosis with 259 market data tables and 17 figures, spread across 903 pages is available at .

Multiple Sclerosis Multiple sclerosis (MS) is a potentially debilitating disease in which body's immune system eats away at the protective sheath (myelin) that covers nerves. Damage to myelin causes interference in the communication between brain, spinal cord and other areas of body. Symptoms include numbness or weakness in one or more limbs, double vision or blurring of vision, tingling or pain in parts of body, fatigue and slurred speech. The predisposing factors include age, gender, family history and certain infections.   The molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 12, 29, 31, 166, 36 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 3, 38 and 2 molecules, respectively.

Some of the companies discussed in this Multiple Sclerosis Pipeline Review, H1 2016 market research report include 4D Pharma Plc, 4SC AG, AB Science SA, AbbVie Inc., Ablynx NV, Acorda Therapeutics, Inc., Actelion Ltd, Addex Therapeutics Ltd, Adhaere Pharmaceuticals, Inc., Aegis Therapeutics, LLC, Affectis Pharmaceuticals AG, Athersys, Inc., Axxam SpA, Baliopharm AG, Bio-Cancer Treatment International Limited, BioAegis Therapeutics, Inc., BIOCAD, Biocon Limited, Biogen, Inc., Biogenomics Limited, Biokine Therapeutics Ltd., Biomar Microbial Technologies, Bionature E.A. Ltd., Bioncotech Therapeutics S.L., Bionovis SA, Bionure Farma, S.L., Biovista Inc., Bird Rock Bio, Inc., Bolder Biotechnology, Inc., BrainStorm Cell Therapeutics Inc., C4X Discovery Holdings PLC, Caladrius Biosciences, Inc., CASI Pharmaceuticals Inc., Catalyst Pharmaceuticals, Inc., Celgene Corporation, Cell Cure Neurosciences, Ltd., Cell2B S.A., Cellceutix Corporation, Chong Kun Dang Pharmaceutical Corp., Cognosci, Inc., Coherus BioSciences, Inc., Commence Bio, Inc., Compugen Ltd., Connexios Life Sciences Pvt. Ltd., Critical Outcome Technologies Inc., CuraVac, Inc., Cyxone AB, Dimerix Bioscience Pty Ltd, Eisai Co., Ltd., Endece, LLC, Euroscreen S.A., Evgen Pharma Plc, Evotec AG, F. Hoffmann-La Roche Ltd., Flex Pharma, Inc., Forward Pharma A/S, FPRT Bio Inc., Gemac, Genervon Biopharmaceuticals, LLC, ,GeNeuro SA, Genzyme Corporation, GlaxoSmithKline Plc, Glialogix, Inc., Hansa Medical AB, Hanwha Chemical Corporation, Harbor Therapeutics, Inc., HitGen LTD, Hutchison MediPharma Limited, Iltoo Pharma, Immune Response BioPharma, Inc., ImmuNext, Inc., Immungenetics AG, InDex Pharmaceuticals AB, Innate Immunotherapeutics Ltd, Inovio Pharmaceuticals, Inc., Io Therapeutics, Inc., Jyant Technologies, Inc., Kadimastem Ltd., Kadmon Corporation, LLC, KAHR medical Ltd., KaloBios Pharmaceuticals, Inc., Kareus Therapeutics, SA, Karo Pharma AB, Karyopharm Therapeutics, Inc., Kezar Life Sciences, Inc., Kineta, Inc., Kyorin Pharmaceutical Co., Ltd., Lead Discovery Center GmbH, LFB S.A., Lipocure Ltd., MacroGenics, Inc., MAKScientific, LLC, Mallinckrodt Plc, Mapi Pharma Ltd., Marathon Pharmaceuticals, LLC, MedAnnex Ltd, MedDay SA, Medestea Research & Production S.p.A., MedImmune, LLC, Meiji Seika Pharma Co., Ltd., Merck KGaA, Meta-IQ ApS, Mitochon Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma Corporation, MorphoSys AG, Neuralstem, Inc., Neuren Pharmaceuticals Limited, Neurotec Pharma SL, New World Laboratories, Inc., Novartis AG, NovImmune SA, Nuevolution AB, Octapharma AG, Omeros Corporation, OncoImmune, Inc., Opexa Therapeutics, Inc., OPKO Health, Inc., OSE Immunotherapeutics, Parvus Therapeutics, Inc., Peptinov SAS, Pfenex Inc., Pfizer Inc., PharmaEssentia Corporation, PharmatrophiX, Inc., Pharmaxis Limited, Pieris Pharmaceuticals, Inc., Plexxikon Inc., ProNoxis AB, Prothena Corporation Plc, Q Therapeutics, Inc., ReceptoPharm, Inc., RedHill Biopharma Ltd., RegeneRx Biopharmaceuticals, Inc., Regenesance BV, Resverlogix Corp., ReveraGen BioPharma, Inc., Rigel Pharmaceuticals, Inc., SanBio, Inc., Santhera Pharmaceuticals Holding AG, Sareum Holdings Plc, SK Biopharmaceuticals Co., Ltd., Sorrento Therapeutics, Inc., Symic Biomedical, Inc., Synthon Holdings BV, Targazyme, Inc., Teikoku Pharma USA, Inc., Teva Pharmaceutical Industries Ltd., Therapix Biosciences Ltd, TikoMed AB, Toleranzia AB, Topas Therapeutics GmbH, TxCell SA, Vaccinex, Inc., Vakzine Projekt Management GmbH, Vertex Pharmaceuticals Incorporated, Virogenomics BioDevelopment, Inc., Vitae Pharmaceuticals, Inc., VivaCell Biotechnology Espana S.L., Xenetic Biosciences (UK) Limited, XL-protein GmbH, Yungjin Pharm. Co., Ltd. and Zydus Cadila Healthcare Limited. Order a copy of Multiple Sclerosis - Pipeline Review, H1 2016 market research report @ .

Another newly published market research report titled on Wegener Polyangiitis - Pipeline Review, H1 2016 reviews pipeline therapeutics for Wegener Polyangiitis by companies and universities/research institutes based on information derived from company and industry-specific sources. Wegener Polyangiitis Pipeline market research report of 60 pages is available at .

Explore more reports on Pharmaceuticals.

About Us: is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441

Connect With Us on:
Twitter: https: //
G+ / Google Plus:

SOURCE ReportsnReports